Accessibility Menu
Apollomics logo

Apollomics(NASDAQ) APLM

Market Cap$58.41MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2021)-97%
5 YearN/A
1 Year+536%
1 Month+52%
$26.43
-0.64%
-0.17Today
Apollomics last closing stock price
MetricPriceDate
Last closeUSD 26.602026-08-28
Apollomics stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+9.34%USD 24.332026-08-21
1 month+52.17%USD 17.482026-07-29
3 month+87.99%USD 14.152026-05-29
Year to date+42.28%USD 18.702025-12-31
1 year+535.6%USD 4.192025-08-28
3 year-94.2%USD 459.002023-08-29
Since inception-97.31%USD 990.002021-11-26

Apollomics Financials at a Glance

Market Cap

$58.41MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$8.70M

Net Income (TTM)

-$64.80M

EPS (TTM)

-$7.57

P/E Ratio

-3.51

Dividend

$0.00

Beta (Volatility)

0.07 (Low)

Price

$26.43

Volume

895.519

Open

$26.43

Previous Close

$26.60

Daily Range

$26.43 - $26.43

52-Week Range

$3.94 - $42.12

Estimated Earnings Date

Sep 24, 2026

APLM News

radiologist of Oncology institute is examing MRI scans

Why Shares of Apollomics Are Up Friday

James HalleyJun 2, 2023
vir biotechnology

Why Shares of Apollomics Soared in March

James HalleyApr 6, 2023

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Apollomics

Apollomics, Inc. is a biotechnology company focused on developing innovative oncology treatments to meet critical unmet medical needs. Established in 2015 and headquartered in Foster City, California, the company operates research and development facilities in California, China, and Australia.

Products and Services
  • APL-101 (Vebreltinib): A selective c-Met inhibitor for non-small cell lung cancer
  • APL-102: An orally administered small molecule targeting liver, breast, and esophageal cancers
  • APL-122: An investigational tumor inhibitor candidate for brain cancers
Growth Outlook
  • Recent quarterly revenue reached $8.5 million, indicating potential market traction
  • Research and development expenses reflect commitment to advancing oncology therapies
  • Strong pipeline with multiple candidates targeting significant cancer types
Financial Highlights
  • Trailing twelve months (TTM) revenue of $8.5 million shows growth potential
  • Net income for the latest quarter was $1.6 million, a positive shift
  • Cash and cash equivalents totaled $3.3 million, supporting ongoing operations
Apollomics, Inc. is positioned in the biotechnology sector with a focus on oncology, addressing significant medical needs through its innovative pipeline. The recent financial performance indicates a potential for growth, particularly with the latest quarterly revenue and net income figures. The company's commitment to research and development is evident, as it continues to advance its therapeutic candidates aimed at various cancer types. With a strong focus on unmet medical needs, Apollomics, Inc. presents an intriguing opportunity for investors interested in the biotechnology field.
AI Generated • Aug 20, 2026

Industry

Biotechnology

Sector

Health Care

Employees

14

CEO

Hung Wen Chen

Website

www.apollomicsinc.com

Headquarters

Foster City, CA 94404, US

APLM Financials

Key Financial Metrics (TTM)

Gross Margin

100.00%

Operating Margin

-111.45%

Net Income Margin

-128.69%

Return on Equity

288.40%

Return on Capital

N/A

Return on Assets

-162.93%

Earnings Yield

-28.49%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$58.41MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

2.20M

Volume

895.519

Avg. Volume

24.46K

Financials (TTM)

Gross Profit

$8.70M

Operating Income

-$51.61M

EBITDA

-$50.53M

Operating Cash Flow

-$57.92M

Capital Expenditure

-$24.00K

Free Cash Flow

-$57.95M

Cash & ST Invst.

$3.28M

Total Debt

$643.00K

Apollomics Performance Analysis

Apollomics annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 0N/A
20232023-12-31USD 0N/A
20242024-12-31USD 0N/A
20252025-12-31USD 8,500,000N/A
Apollomics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-06-30430.9%
Q42024-12-31-188.8%
Q22025-06-30641.4%
Q42025-12-31-100.0%
Apollomics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -61.60162.6%
20232023-12-31USD -231.96276.6%
20242024-12-31USD -52.80-77.2%
20252025-12-31USD -7.57-85.7%
Apollomics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-06-30-15733.3%
Q42024-12-3155.5%
Q22025-06-3032.8%
Q42025-12-31133.4%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2025YOY CHG

Revenue

$0.00

-100.0%

Gross Profit

$0.00

-100.0%

Gross Margin

0.00%

N/A

Market Cap

$58.41MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$4.17M

N/A

Employees

14

N/A

Net Income

$1.60M

+107.3%

EBITDA

$3.03M

+110.9%

Quarterly Fundamentals

Name
Q4 2025YOY CHG

Total Cash

$3.28M

-91.3%

Total Debt

$643.00K

-86.2%

Accounts Receivable

$2.49M

+434.3%

Inventory

$0.00

N/A

Long Term Debt

$434.00K

+62.5%

Short Term Debt

$209.00K

-95.2%

Return on Assets

-1.63%

N/A

Return on Invested Capital

-24.41%

N/A

Free Cash Flow

-$10.37M

+57.5%

Operating Cash Flow

-$10.37M

+57.5%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
ADAPAdaptimmune Therapeutics plc
$0.05-3.00%
LPTXLeap Therapeutics, Inc.
$0.77-3.15%
ATHAAthira Pharma, Inc.
$6.75-6.12%
BLRXBioLineRx Ltd.
$2.75+5.60%

Trending Stocks

Symbol / CompanyPricePrice Chg
PCGPG&E
$13.56-0.18%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$9.85+0.10%
NVDANvidia
$220.14+0.01%
BITOProShares Trust - ProShares Bitcoin ETF
$10.60+0.01%

Questions About APLM

What is the current price of Apollomics?

Apollomics is trading at $26.43 per share.

What is the 52-week range for Apollomics?

Over the past 52 weeks, Apollomics has traded between $3.94 and $42.12.

How much debt does Apollomics have?

As of the most recent reporting period, Apollomics reported total debt of $643.00K.

How much cash does Apollomics have on hand?

Apollomics reported $3.28M in cash and cash equivalents in its most recent financial results.

What is Apollomics’s dividend yield?

Apollomics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services